Status:
TERMINATED
Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Heart Failure
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Prior studies have shown that left ventricular assist device (LVAD) implantation commonly results in right ventricular failure (RVF). Right ventricular dysfunction and failure after LVAD implantation ...
Detailed Description
Prior studies have shown that left ventricular assist device (LVAD) implantation commonly results in right ventricular failure (RVF). Right ventricular dysfunction and failure after LVAD implantation ...
Eligibility Criteria
Inclusion
- Ages 18-75
- Accepted for LVAD implantation by MGH multidisciplinary team
Exclusion
- Disorders of the pulmonary artery wall that would preclude placement or correct positioning of RVAD
- Presence of mechanical valves
- Mural thrombosis of the right atrium or vena cava
- Anatomic conditions precluding insertion of the RVAD
- Complicated venous access precluding or complicating device placement (i.e. femoral and jugular thrombosis)
- No evidence of right ventricular dysfunction by echocardiogram
Key Trial Info
Start Date :
May 12 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
161 Patients enrolled
Trial Details
Trial ID
NCT04458103
Start Date
May 12 2020
End Date
June 1 2023
Last Update
July 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114